New Bill Would Remove Financial Penalties for Participating in Research Studies
Site Search
Showing 31 - 34 of 34 results
Press Release
|
June 15, 2009
|
3 min read
This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
News
|
June 24, 2014
|
4 min read
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Press Release
|
April 3, 2024
|
3 min read
This is an exciting time in cystic fibrosis clinical research. Not only are there several clinical trials of therapies to treat the underlying cause of CF, but there are also many trials to treat key symptoms of CF and improve quality of life. These include studies of antibiotics and anti-inflammatories to treat lung infections and inflammation, as well as treatments to improve nutrition and digestion.